Your browser does not support JavaScript! CYTRA-K (POTASSIUM CITRATE AND CITRIC ACID) LIQUID [CYPRESS PHARMACEUTICAL, INC.]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

CYTRA-K (potassium citrate and citric acid) liquid
[Cypress Pharmaceutical, Inc.]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL unapproved drug other
NOTE:THIS DRUG HAS NOT BEEN FOUND BY FDA TO BE SAFE AND EFFECTIVE, AND THIS LABELING HAS NOT BEEN APPROVED BY FDA. For further information about unapproved drugs, click here.
Drug Label Sections

Cytra-K Oral Solution

Rx Only
NDC 60258-003-16


DESCRIPTION
Cytra-K Oral Solution is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate and citric acid in a sugar-free, non alcoholic base.

CYTRA-K Oral Solution contains in each teaspoonful (5 mL):
Potassium Citrate Monohydrate.................................1100 mg
Citric Acid Monohydrate..............................................334 mg

Each mL contains 2 mEq potassium ion and is equivalent to 2 mEq bicarbonate (HCO3).

INACTIVE INGREDIENTS

propylene glycol, sorbitol, polyethylene glycol, methylparaben, propylparaben, sucralose, FD and C red #40, cherry flavor, and purified water.

ACTIONS

Potassium citrate is absorbed and metabolized to potassium bicarbonate, this acting as a systemic alkalizer.  The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently.  Oxidation is virtually complete so that less that 5% of the potassium citrate is excreted in the urine unchanged.

INDICATIONS AND USAGE

Cytra-K Oral Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated.  In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine.  It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable.  This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose.  This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage.  It is highly palatable, pleasant tasting and tolerable, even when administered for long periods.  Potassium citrate does not neutralize the gastric juice or disturb digestion.

CONTRAINDICATIONS

Severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, and hyperkalemia from any cause.  Known hypersensitivity to any ingredient.

WARNINGS

There have not been several reports, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of  enteric-coated thiazides with potassium salts.  These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics.  These small-bowel lesions have caused obstruction, hemorrhage, and perforation.  Surgery was frequently required and deaths have occurred.  Based on a large survey of physicians and hospitals, both United States and foreign, the incidence of these lesions is low, and a causal relationship in man has not been definitely established.  Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously.  Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastrointestinal bleeding occur.

Large doses may cause hyperkalemia an alkalosis, especially in the presence of renal disease.  Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity.  Do not exceed recommended dosage.  Discontinue use if adverse reaction occurs.

PRECAUTIONS

Should be used with caution by patients with low urinary output unless under the supervision of a physician.  As with all liquids containing a high concentration of potassium, patients should be directed to diluted adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferable, to take each dose after meals to avoid saline laxative effect.

ADVERSE REACTIONS

Cytra-K Oral Solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output.  However, as with any alkalinizing agent caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis.  Potassium intoxication causes restlessness, weakness, mental confusion, tingling of extremities, and other symptoms associated with a high concentration of potassium in the serum.  Periodic determinations of serum electrolytes should be carried out in those patients with renal disease in order to avoid these complications.  Hyperkalemia may exhibit the following electrocardiographic abnormalities:  Disappearance of the P wave, widening and slurring of QRS complex, changes of the S-T segment, tall peaked T waves, etc.

OVERDOSAGE

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia.  However,  if excretory mechanisms are impaired, hyperkalemia can result (see Contraindications and Warnings).  Hyperkalemia, when detected, must be treated immediately because lethal levels can be reached in a few hours.

TREATMENT OF HYPERKALEMIA
Should hyperkalemia occur, treatment measures include the following:  (1) Elimination of foods or medications containing potassium.  (2) The intravenous administration of 300 to 500 mL/hr of dextrose solution (10 to 25%), containing 10 units of insulin/20 gm dextrose.  (3) The use of exchange resins, hemodialysis, or peritoneal dialysis.  In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the plasma potassium concentration can produce digitalis toxicity.

DOSAGE AND ADMINISTRATION

Cytra-K Oral Solution should be taken diluted in water according to directions, followed by additional water, if desired.  Palatability is enhanced if chilled before taking.

Proper dilution may help prevent gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.

Usual Adult Dose:  3 to 6 teaspoonfuls (15 to 30 mL), diluted with 1 glass of water, after meals and at bedtime, or as directed by a physician.
Usual Pediatric Dose:  1 to 3 teaspoonfuls (5 to 15 mL), diluted with 1/2 glass of water, after meals and at bedtime, or as directed by a physician.
Usual Dosage Range:  2 to 3 teaspoonfuls (10 to 15 mL), diluted with a glassful of water, taken four times a day.  Cytra-K Oral Solution, diluted with a glassful of water, taken four times a day will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects.  To check urinary pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.

HOW SUPPLIED

Cytra-K Oral Solution is a (red colored; cherry flavored) oral solution and is supplied in the following oral dosage form:
NDC 60258-003-16 (16 fl oz bottles).

STORAGE

Keep tightly closed.  Store at controlled room temperature, 20°-25°C (68°-77°F).  Protect from excessive heat and freezing.

Tamper evident by foil seal under cap.  Do not use if foil seal is broken or missing.

Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.  IN CASE OF ACCIDENTAL OVERDOSAGE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.

Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088 (Toll Free).

Manufactured by
Cypress Pharmaceuticals, Inc.
Madison, MS  39110

I352 Rev. 09/10

PRODUCT PACKAGING

The packaging below represents the labeling currently used.

Principal display panel and side panel for 473 mL label:

NDC 60258-003-16

CYTRA-K
ORAL SOLUTION

(POTASSIUM CITRATE AND
CITRIC ACID ORAL SOLUTION USP)

1100 mg/334 mg per 5 mL

A SUGAR-FREE SYSTEMIC ALKALIZER

EACH TEASPOONFUL (5 mL) CONTAINS:
POTASSIUM CITRATE MONOHYDRATE....................1100 mg
CITRIC ACID MONOHYDRATE.....................................334 mg

Each mL contains 2 mEq Potassium Ion, and is equivalent to
2 mEq Bicarbonate (HCO3).

Rx Only

CYPRESS
PHARMACEUTICALS, INC
.

16 fl oz (473 mL)

INDICATIONS AND USAGE:
Cytra-K Oral Solution is a stable and pleasant-tasting oral systemic alkalizer.  It is effective for long-term maintenance of an alkaline urine, especially when the administration of sodium salts is undesirable or contraindicated.

SEE ACCOMPANYING LITERATURE.

DOSAGE AND ADMINISTRATION:  SHAKE WELL BEFORE USING.

Usual Adult Dose:  3 to 6 teaspoonfuls (15 to 30 mL) DILUTED with 1 glass of water, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose:  1 to 3 teaspoonfuls (5 to 15 mL) DILUTED with 1/2 glass of water, after meals and at bedtime, or as directed by a physician.

Proper dilution may help prevent gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.

STORAGE:  Keep tightly closed.  Store at controlled room temperature, 20°-25°C (68°-77°F).  Protect from excessive heat or freezing.

Tamper evident by foil seal under cap.  Do not use if foil seal is broken or missing.

Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
IN CASE OF ACCIDENTAL OVERDOSAGE, SEEK PROFESSIONAL ASSISTANCE
OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.


Call your doctor for medical advice about side effects.  You may report side effects to FDA
at 1-800-FDA-108 (Toll Free).

Manufactured for:  Cypress Pharmaceutical, Inc., Madison, MS  39110  L652  Rev. 09/10


CYTRA-K Packaging


CYTRA-K Packaging


CYTRA-K Packaging



CYTRA-K 
potassium citrate and citric acid liquid
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:60258-003
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Potassium Citrate (Potassium Cation) Potassium Citrate1100 mg  in 5 mL
Citric Acid Monohydrate (Bicarbonate Ion) Citric Acid Monohydrate334 mg  in 5 mL
Product Characteristics
Color    Score    
ShapeSize
FlavorCHERRYImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:60258-003-16473 mL in 1 BOTTLE, PLASTIC
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other09/30/2008
Labeler - Cypress Pharmaceutical, Inc. (790248942)

Revised: 3/2011
 
Cypress Pharmaceutical, Inc.

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services